Registry for cell therapy in non-ischemic dilated heart muscle disease
Part of Genetic & congenital, Heart & circulation clinical trials.
This is a research registry that follows people with non-ischemic dilated cardiomyopathy (a weakened heart muscle) who are already on the right medications. It helps doctors better understand how cell-based therapy and related care affect heart function over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old
- You have dilated cardiomyopathy that is not caused by blocked heart arteries (non-ischemic)
- You have been on the best available heart medicines for at least 6 months
- Your heart pumping strength (left ventricular ejection fraction) is under 40%
- Your symptoms are at New York Heart Association class III, and this has been stable on medications for at least 3 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether injecting special cells (cell therapy) can help the heart recover in people with advanced heart failure who are getting a mechanical heart pump (LVAD). It may offer a new way to improve heart function and quality of life.
This trial tests whether heart muscle cells made from stem cells, injected into the heart, can improve heart function in people with heart failure and a weak heart pump. It may be an option for those who are not getting enough help from other treatments.
This Phase 2 trial tests whether donor “MSC” cells can improve heart function in people with non-ischemic dilated cardiomyopathy and reduced pumping strength. You may be eligible if your condition is already treated with standard heart medicines and you can safely undergo a heart catheterization and follow-up testing.
This trial is a registry, meaning it collects health information to help doctors study heart muscle diseases and plan future cardiovascular studies. You may be able to join if you have a non-ischemic cardiomyopathy such as dilated cardiomyopathy, certain forms of thick heart muscle, non-compaction, or arrhythmogenic right-sided disease.
This study tests whether a single intravenous infusion of stem cells from donated newborn tissue is safe for people aged 4 to 39 with dilated cardiomyopathy (a weakened, enlarged heart). It aims to find a new option for those who haven't improved enough with standard heart failure medications.
This study enrolls people with certain types of heart muscle diseases to learn how blocked heart arteries and tiny blood vessels affect symptoms and outcomes. It may help researchers better understand these conditions and improve future care.
Hear when a new Cardiomyopathy, Dilated trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.